Compare STAA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | CSTL |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.9M | 806.3M |
| IPO Year | 1995 | 2019 |
| Metric | STAA | CSTL |
|---|---|---|
| Price | $17.45 | $25.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $22.19 | ★ $47.17 |
| AVG Volume (30 Days) | ★ 1.2M | 396.6K |
| Earning Date | 03-03-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $239,442,000.00 | ★ $344,229,000.00 |
| Revenue This Year | $33.83 | $2.42 |
| Revenue Next Year | $8.16 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $14.69 | $14.59 |
| 52 Week High | $30.81 | $44.28 |
| Indicator | STAA | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 28.81 |
| Support Level | $17.13 | $24.89 |
| Resistance Level | $18.19 | $34.97 |
| Average True Range (ATR) | 0.96 | 1.05 |
| MACD | 0.00 | 0.13 |
| Stochastic Oscillator | 22.26 | 16.96 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.